A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


July 24, 2012

Test-and-Treat Has Cost Versus Benefit Considerations

by Laura Whitehorn

AIDS 2012Where financial resources are limited, targeting groups at high risk for HIV infection for testing and immediate treatment is more cost effective than a community-wide test-and-treat initiative, according to New York City modeling data presented Monday, July 23, at the XIX International AIDS Conference in Washington, DC.

Public health initiatives are moving away from risk-based testing to identify people in need of care and antiretroviral (ARV) therapy and now beginning to focus on testing all adults living with HIV in the general population, said Jason Kessler, MD, of New York University School of Medicine, the lead author of the presented research. Whether or not this should be a priority in areas where the resources may be limited in terms of providing adequate care and support for people found to be living with the virus remains a matter of controversy.

TLC-Plus is a test-and-treat initiative being evaluated in HIV Prevention Trials Network study 065 (HPTN 065), currently under way in New York City and Washington, DC. It involves community-wide HIV testing and, for those found to be positive for the virus, linkage to care, immediate treatment and supportive services.

Kessler and his colleagues at the New York City Department of Health and Mental Hygiene used statistical modeling to determine the usefulness and cost-effectiveness of TLC-Plus, executed according to its original design or modified to focus primarily on populations at high risk for HIV infection (e.g., men who have sex with men and/or injection drug users).

Over a 20-year period, Kessler and his colleagues estimated that there would be roughly 59,000 new HIV infections in New York City in the absence of TLC-Plus.

TLC-Plus with immediate ARV therapy could avert 20 percent of these infections in New York City—roughly 47,600 new infections, down from 59,000—provided that it is implemented in the general population of city residents.

More “focused” prioritization, the researchers’ modeling found, resulted in fewer infections averted overall. Prioritization to populations at higher risk for HIV transmission and or acquisition, Kessler explained, only retained 14 to 68 percent of the overall effect.

These compromises, however, came with reduced total costs and cost-per-infection averted. Whereas the cost-per-infection averted would be more than $1.5 million under the general community roll-out of TLC-Plus, a roll-out of TLC-Plus targeting high-risk individuals would come with a cost-per-infection averted of $360,000.

“Without consideration of costs it makes most sense to roll [TLC-Plus] out to as many people as you can possibly reach,” Kessler said. “When you bring cost into the equation—you want to optimize the bang for your buck—it makes the most sense to prioritize your intervention on the highest risk groups.”

Given limited budgets, he concluded, the analysis favors targeting high-prevalence populations and neighborhoods for TLC-Plus.

Search: tlc-plus, hiv, test and treat, treatment, prevention, new york city, cost, benefit, kessler, aids 2012

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.